Genetic alterations of PIK3CA and tumor response in patients with locally advanced cervical squamous cell carcinoma treated with cisplatin-based concurrent chemoradiotherapy

• Published in: Experimental and molecular pathology Vol. 98; no. 3; pp. 407 - 410
• Main Authors: Wang, Juan, Chai, Yan-lan, Wang, Tao, Liu, Jin-hui, Dai, Peng-gao, Liu, Zi
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Inc 01.06.2015
• Subjects: Antineoplastic Agents - therapeutic use; Carcinoma, Squamous Cell - genetics; Carcinoma, Squamous Cell - therapy; Cervical carcinoma; Chemoradiotherapy; Cisplatin - therapeutic use; Class I Phosphatidylinositol 3-Kinases; DNA Copy Number Variations; Female; Genetic alterations; Humans; Middle Aged; Mutation; Phosphatidylinositol 3-Kinases - genetics; PIK3CA; Response; Treatment Outcome; Uterine Cervical Neoplasms - genetics; Uterine Cervical Neoplasms - therapy; Response; Cervical carcinoma; PIK3CA; Chemoradiotherapy; Genetic alterations
• ISSN: 0014-4800; 1096-0945
• DOI: 10.1016/j.yexmp.2015.03.014

The objective of this study was to investigate the predictive value of common genetic alterations of PI3K/AKT/mTOR and Ras/Raf/MAPK pathways in patients with locally advanced cervical squamous cell carcinoma (LACSCC) treated with cisplatin-based concurrent chemoradiotherapy (CCRT). Patients with LACSCC, treated at a single institution with CCRT were eligible for this retrospective study. A total of sixty pre-treatment tumor biopsies were retrieved. Somatic mutations were detected by pyrosequencing and CNV was determined by quantitative realtime PCR. The association of genetic alterations with clinicopathological characteristics and treatment response were analyzed. Patients without genetic alterations (mutations or amplification) of PIK3CA had a significantly higher response rate than patients with these alterations (p=0.006). In the logistic regression analysis, PIK3CA genetic alterations retained an independent factor in predicting response to CCRT. Somatic mutations and copy number amplification of PIK3CA were associated with response to CCRT in patients with cervical squamous cell carcinoma.